Metabolic Acidosis Market

Market Overview:

The 7 major metabolic acidosis markets are expected to exhibit a CAGR of 5.76% during 2024-2034.

The metabolic acidosis market has been comprehensively analyzed in IMARC's new report titled "Metabolic Acidosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Metabolic acidosis is a medical condition characterized by an imbalance in the body's acid-base balance, resulting in an excess of acid or a decrease in bicarbonate levels. This ailment can disrupt normal bodily functions and potentially cause various health problems, like bone loss and inflammation. The common symptoms of the illness include rapid breathing (hyperventilation), confusion, fatigue, vomiting, dizziness, nausea, loss of appetite, weakness, upset stomach, headache, lethargy, rapid heartbeat, etc. In severe cases, individuals suffering from this condition may also experience shock, coma, or even death. The diagnosis of metabolic acidosis typically requires a combination of medical history assessment, clinical feature evaluation, and physical examination. The healthcare provider may perform arterial blood gas analysis or a comprehensive metabolic panel to detect abnormal levels of various electrolytes and metabolic markers, like bicarbonate, glucose, sodium, potassium, chloride, etc. Depending on the suspected causative factors of the disorder, further investigations may be necessary to validate a diagnosis. These may include blood glucose measurement, blood ketone testing, renal and liver function tests, toxicology screens, etc.

The increasing cases of kidney disorders that can impair the kidneys' ability to eliminate acid from the body, thereby leading to acid buildup, are primarily driving the metabolic acidosis market. In addition to this, the rising incidences of various associated risk factors, such as ingestion of toxins, uncontrolled diabetes, starvation or prolonged fasting, inborn errors of metabolism, etc., are creating a positive outlook for the market. Moreover, the widespread adoption of intravenous fluids that help to restore fluid and electrolyte balance, thereby correcting dehydration and improving acid-base equilibrium among patients, is further bolstering the market growth. Apart from this, the escalating utilization of inotropic agents, since they enhance cardiac output and blood flow to various organs, which can mitigate the adverse effects of reduced tissue oxygenation and nutrient delivery associated with the condition, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of hydrochloric acid binders to treat this disease on account of their several benefits, such as alleviating discomfort, promoting healing of the esophagus and stomach lining, and helping restore a healthier acid balance, is expected to drive the metabolic acidosis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the metabolic acidosis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for metabolic acidosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the metabolic acidosis market in any manner.

Key Highlights:

• Metabolic acidosis is a common complication of chronic kidney disease (CKD), affecting 15% of patients.
• Metabolic acidosis is more likely in people with advanced stages of CKD.
• Metabolic acidosis has been observed to range between 2 and 13% in people with stage 3 CKD and 19 to 37% in patients with stage 4 CKD.
• Metabolic acidosis may also arise during critical diseases and hospitalizations, with an incidence of 14-42%.
• Infants who developed metabolic acidosis were much more likely to be born prematurely and at a younger age than those who did not.

Drugs:

TRC101 is a high-capacity, selective, non-absorbed polymer that binds hydrochloric acid and is being investigated as a therapy for metabolic acidosis. The drug works by binding to and eliminating hydrochloric acid from the gastrointestinal system, which raises serum bicarbonate and corrects metabolic acidosis.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the metabolic acidosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the metabolic acidosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current metabolic acidosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the metabolic acidosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the metabolic acidosis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the metabolic acidosis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of metabolic acidosis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of metabolic acidosis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of metabolic acidosis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with metabolic acidosis across the seven major markets?
• What is the size of the metabolic acidosis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of metabolic acidosis?
• What will be the growth rate of patients across the seven major markets?
   

Metabolic Acidosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for metabolic acidosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the metabolic acidosis market?
• What are the key regulatory events related to the metabolic acidosis market?
• What is the structure of clinical trial landscape by status related to the metabolic acidosis market?
• What is the structure of clinical trial landscape by phase related to the metabolic acidosis market?
• What is the structure of clinical trial landscape by route of administration related to the metabolic acidosis market?